Merck (MRK 0.34%) announced this week that its experimental anesthesia reversal drug sugammadex was rejected by the Food and Drug Administration. This isn't the only drug that the big pharma company has failed to get past the FDA this year; its insomnia drug suvorexant was also rejected earlier in 2013. What does this most recent rejection mean for investors, and is Merck making the right changes to its research and development structure? In the following video, a segment from The Motley Fool's health care show Market Checkup, analysts Max Macaluso and David Williamson discuss the impact of the FDA's decision.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Can Merck Recover From This FDA Rejection?
NYSE: MRK
Merck

Merck's latest setback comes from the Food and Drug Administration's rejection of sugammadex.
Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned



*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.